Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Reunion Neuroscience Inc C.FTRP


Primary Symbol: T.REUN

Healthcare Biotechnology
Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.


TSX:REUN - Post by User

Reunion Neuroscience Inc > Renderings of Field Trip's Jamaica Facility
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(17)
•••
Post by PsilocybinAlphaon Nov 04, 2020 2:37pm
270 Views
Post# 31836561

Renderings of Field Trip's Jamaica Facility

Renderings of Field Trip's Jamaica Facility

Field Trip Health has shared renderings of their Jamaican facility with Psilocybin Alpha.

The facility will be developed and managed by Field Trip Natural Products Limited, the Jamaican subsidiary of Field Trip Health. It will be built on The University of the West Indies’ (UWI) Mona campus, near the Caribbean country’s capital, Kingston.

Images here.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities